SAN FRANCISCO (AP) - VaxGen Inc.'s troubled $877.5 million federal contract to produce a new anthrax vaccine hit another snag Friday that delayed delivery of the shots a third time and jeopardized the struggling company's future.
The Food and Drug Administration is concerned the vaccine will lose its potency too fast to be effective and halted a pivotal human test of the experimental drug, the company said. In a conference call with analysts, VaxGen officials said the vaccine lost potency over time, but its scientists didn't believe the loss was significant.
Chief Executive Officer Lance Gordon said company officials hoped to meet with FDA officials soon to discuss the agency's refusal to allow the human test to begin.
Shares of the Brisbane-based company plummeted more than 55 percent, losing $2.22 to close at $55.64 in Friday trading on an electronic bulletin board exchange.
The FDA's demands will further delay delivery of 25 million genetically engineered doses that VaxGen was supposed to begin shipping this month under the contract it won two years ago from the U.S. Department of Health and Human Services.
Because the company won't begin the human test on time, the federal government can cancel the contract. The company won't receive any payments until it begins delivery. The department is its only customer.
"That is the risk associated with the contract," VaxGen executive James Panek said.
The department sent VaxGen a letter Friday, giving the company 10 days to explain how it intends to address the FDA's concerns, Health and Human Services spokesman Bill Hall said. He said no decision has been made about what the agency will do with the contract.
"Medical research is an unpredictable process," Hall said. "It is not unexpected that delays can be met along the way."
The VaxGen contract was supposed to be the crown jewel of Project Bioshield, a $5.6 billion government program prompted by the 2001 anthrax attacks. Bioshield's goal is to build national drug stockpiles in case of a bioterror attack. The project was supposed to jump start a national security renaissance among drug makers by guaranteeing contracts to develop drugs for combatting potential bioweapons.
VaxGen's shots were intended to replace the current vaccine, which requires six shots administered over 18 months. VaxGen's is expected to require no more than three shots.
Since winning the contract, however, VaxGen has repeatedly stumbled, starting with its disclosure it would miss the original deadline of November 2005 by a year.
Even before winning the contract, the Brisbane-based company had a checkered past highlighted by the 2003 flop of its experimental AIDS vaccine, which failed to protect inoculated volunteers from getting infected.
Since then, it was dropped from the Nasdaq Stock Market in 2004 for failing to file financial reports. The company also has been told by the FDA to change misleading claims about the vaccine in a sales brochure, and its chief scientific officer left the company in July.
In March, the government said it wouldn't pay VaxGen until the company completed a costly and time-consuming human test to ensure the vaccine was safe. The new requirement forced the company to sell its stake in another biotech company for $79 million to stay afloat and finance the new test.
On Friday, the company told analysts it had enough cash to stay in business through 2007.
Posts: 259 | From: Humble, Tx. | Registered: Jul 2005
| IP: Logged |
Mike, the anthrax vaccines we received were lots that had been sitting on the shelves past their expiration dates and were never inspected by the FDA. The manufacturer, Bioport (now goes by another name) has undergone a lot of morphing publically to distance itself from its bad reputation since the Gulf War.
Just read some of these reports from the FDA. Whereas these particular reports are fairly recent, they are an example of the earlier reports and problems Bioport faced in issuing the anthrax vaccine. All you have to do is go to the FDA homepage ( http://www.fda.gov/ ) and do a search for "Bioport" and you will find some very interesting revealations.
1. A portion of the lot was labeled with an expiration date of September 8, 2001, rather than the correct expiration date of February 3, 2001. Bioport employees will be traveling to distribution points and correcting the mislabeled vials: http://www.fda.gov/cber/recalls/anthbio083000.htm
(c) 1999-2005. INDIVIDUAL MEMBERS RESERVE ALL RIGHTS TO THEIR POSTINGS ON THIS BULLETIN BOARD WHERE COPYRIGHT IS NOT EXPLICITLY DISCLAIMED. (KANSAS CITY, MO.) *** Junior members, members, moderators, and administrators reserve common-law copyright privileges and rights to their own individual postings, unless expressly disclaimed. By using this bulletin board and in consideration for the privileges of such use, all guests, junior members, members, moderators, and administrators irrevocably agree to grant AGWVA permission and consent to use, store, retrieve, copy, distribute, and edit such message postings without limitation or exception, and irrevocably appoints AGWVA as agent for the purpose of execting any document or instrument necessary to effectuate this agreement. Furthermore, by using this bulletin board and in consideration therefor, all authorized or unauthorized guests, junior members, members, moderators, and administrators agree that the controlling jurisdiction over any dispute or controversy arising from the use or access of this bulletin board shall be governed under the laws of the State of Missouri and jurisdiction of the Circuit Court of Clay County, Missouri. *** While we encourage private messages to be posted in private forums requiring special authorization to enter, some messages on this bulletin board are protected by attorney-client privilege, doctor-patient privilege, and/or priest-penitent privilege, and such messages are intended solely for the use of those posting those messages, the intended recipient of that message, and AGWVA Bulletin Board's management - any disclosure beyond these parties is unintentional. The voluntary provision of medical, regulatory services/VA-representation, or religious services to members of the AGWVA Bulletin Board shall be limited by the case-by-case circumstances of each situation and shall be provided or not provided at the sole discretion of the person providing such services with the understanding that such services may stop or be limited at any time. Voluntary provision of any such service does not guarantee or assure any person a future or further right to such services. *** For posting messages to or from this bulletin board, AGWVA's management (moderators and administrators) are not compensated, directly or indirectly. *** Unauthorized use, copying, or distribution of material posted to this bulletin board is prohibited. Unauthorized access to this bulletin board is illegal and AGWVA reserves the right to prosecute anyone attempting to illegally access this bulletin board. AGWVA has stated explicit rules of conduct for its members posting on this bulletin board and all such rules are incorporated herein by reference as if fully set out hereinbelow. ***